February 2021
-
PET vs. CT in Lung Cancer Surveillance: The ‘Pro’ Side from the Nuclear Medicine Perspective
A significant proportion of patients with stage I to III NSCLC or SCLC will have locoregional or distant metastases following curative-intent therapy. Studies have reported local recurrence rates of 22% […]
-
Patient Perspectives on CT and PET Scans: Imaging Technology Provides Different Benefits, Drawbacks for Each Individual Patient
For patients with metastatic lung cancer, frequent scans are a stark reality of living with cancer. Although most scans happen every 3 months, some clinical trials require scans more often […]
-
Mutation or Amplification: Who MET the Expectations?
Identification of driver oncogenes in NSCLC is leading the method for accurate patient selection and proper targeting of actionable alterations. Several molecular events have been described, and different biomarkers are […]
-
Large LDCT Lung Cancer Screening Program Suggests Screening Benefits Far Outweigh the Risks
Lung cancer screening saves lives. This once controversial statement has now been validated in recent large, randomized trials of low-dose computed tomographic (LDCT) lung cancer screening (LCS) including the National […]
-
FDG PET–CT Versus CT for Lung Cancer Surveillance: The "Con" Side
Lung cancer remains the leading cause of cancer-related deaths.1 Advances in early detection of lung cancer following the implementation of screening programs and the availability of newer therapies have increased […]
-
Possible Benefits of Metformin for Lung Cancer Still Unknown
Ben Levy, MD When it comes to the use of metformin as a treatment for lung cancer, the jury is still out on its potential. “Metformin’s utility as an anticancer […]
-
RET Therapy for NSCLC, a New Generation of Inhibitors
Therapies for NSCLC have evolved over the past 2 decades to account for the specific biology of the tumor and have improved outcomes for a multitude of patients. Discovery of […]
-
Tyrosine kinase inhibitors (TKI) or monoclonal antibodies (mAb) for the Treatment of NRG1 and, Potentially, NRG2 Fusion–Positive Malignancies
When patients with advanced metastatic NSCLC initially make their way into our medical oncology clinic, one of the first things we check for is the molecular pathology testing report, in […]
-
Vemurafenib Alone and Combination for Lung Cancer: A Conversation with Marcelo V. Negrao, MD
Dr. Negrao is an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center. Dr. Negrao has a diverse experience in […]
-
Patient Advocacy Groups Fund EGFR-related Research
Christine Lovly, MD, PhD Christine Lovly, MD, PhD, and Helena Yu, MD, have been awarded the 2021 EGFR Resisters/LUNGevity Lung Cancer Research Award. Each award totals $200,000 for a two-year […]
View ILCN Archives
Provider Resources